Disruption:Article Title: Targeting growth hormone in cancer: future perspectives.
Article Snippet: While results from genetic studies are persuasive, deficiency in GH signalling, for example, through Gh1/Ghr gene disruption or constitutive expression of a GHR/Ghr antagonist, would be expected to affect initial tumour establishment and growth prior to Downloaded from Bioscientifica.com at 10/07/2023 01:32:49AM via free access https://erc.bioscientifica.com © 2023 the author(s) Printed in Great Britain Published by Bioscientifica Ltd.https://doi.org/10.1530/ERC-23-0033 Prostate Pten-mutant mouse prostate cancer cell (↓) Pegvisomant, 100 mg/kg, 3 times per week IGF1: 18% reduction (3 days after the final injection) (Unterberger et al. 2022) Monotherapy-reduced Ptenmutant prostate tumour growth Hepatocellular HepG2 (↓) Pegvisomant, 100 mg/kg, daily IGF1: ~80% reduction (Kaseb et al. 2022) Monotherapy-reduced tumour growth; reduction was more pronounced when combined with sorafenib Gastric SUN-16 (↓) Pegvisomant, 250 mg/kg, daily IGF-1: not described (Meng et al. 2022) Monotherapy: inhibition of tumour growth Pancreatic PANC1 (↓) Pegvisomant, 10 mg/kg/day; Compound G, 10 mg/kg/day IGF1: not described (Brody et al. 2021) Monotherapy: PEG and compound G decreased tumour growth GEM combined with PEG or compound G was more efficacious Breast MCF-7 (↓) GHR/PRLR neutralising mAb; 15 or 30 mg/kg, twice weekly IGF1: not described (Chen et al. 2020) T-47D (↓) Monotherapy: inhibited the growth of T-47D and MCF-7 Breast MDA-MB-231 (↓) Small-molecule BM 001–003, 1 and 5 mg/kg, 3 times per week IGF1: 73% reduction (van der Velden et al. 2022)Monotherapy: all three reduced tumour growth; BM001 was most effective (↓) indicates cell lines for which efficacy with GHR antagonism was observed either as a single agent or in combination therapy, while (–) indicates no effect.
Expressing:Article Title: Targeting growth hormone in cancer: future perspectives.
Article Snippet: While results from genetic studies are persuasive, deficiency in GH signalling, for example, through Gh1/Ghr gene disruption or constitutive expression of a GHR/Ghr antagonist, would be expected to affect initial tumour establishment and growth prior to Downloaded from Bioscientifica.com at 10/07/2023 01:32:49AM via free access https://erc.bioscientifica.com © 2023 the author(s) Printed in Great Britain Published by Bioscientifica Ltd.https://doi.org/10.1530/ERC-23-0033 Prostate Pten-mutant mouse prostate cancer cell (↓) Pegvisomant, 100 mg/kg, 3 times per week IGF1: 18% reduction (3 days after the final injection) (Unterberger et al. 2022) Monotherapy-reduced Ptenmutant prostate tumour growth Hepatocellular HepG2 (↓) Pegvisomant, 100 mg/kg, daily IGF1: ~80% reduction (Kaseb et al. 2022) Monotherapy-reduced tumour growth; reduction was more pronounced when combined with sorafenib Gastric SUN-16 (↓) Pegvisomant, 250 mg/kg, daily IGF-1: not described (Meng et al. 2022) Monotherapy: inhibition of tumour growth Pancreatic PANC1 (↓) Pegvisomant, 10 mg/kg/day; Compound G, 10 mg/kg/day IGF1: not described (Brody et al. 2021) Monotherapy: PEG and compound G decreased tumour growth GEM combined with PEG or compound G was more efficacious Breast MCF-7 (↓) GHR/PRLR neutralising mAb; 15 or 30 mg/kg, twice weekly IGF1: not described (Chen et al. 2020) T-47D (↓) Monotherapy: inhibited the growth of T-47D and MCF-7 Breast MDA-MB-231 (↓) Small-molecule BM 001–003, 1 and 5 mg/kg, 3 times per week IGF1: 73% reduction (van der Velden et al. 2022)Monotherapy: all three reduced tumour growth; BM001 was most effective (↓) indicates cell lines for which efficacy with GHR antagonism was observed either as a single agent or in combination therapy, while (–) indicates no effect.
Injection:Article Title: Targeting growth hormone in cancer: future perspectives.
Article Snippet: While results from genetic studies are persuasive, deficiency in GH signalling, for example, through Gh1/Ghr gene disruption or constitutive expression of a GHR/Ghr antagonist, would be expected to affect initial tumour establishment and growth prior to Downloaded from Bioscientifica.com at 10/07/2023 01:32:49AM via free access https://erc.bioscientifica.com © 2023 the author(s) Printed in Great Britain Published by Bioscientifica Ltd.https://doi.org/10.1530/ERC-23-0033 Prostate Pten-mutant mouse prostate cancer cell (↓) Pegvisomant, 100 mg/kg, 3 times per week IGF1: 18% reduction (3 days after the final injection) (Unterberger et al. 2022) Monotherapy-reduced Ptenmutant prostate tumour growth Hepatocellular HepG2 (↓) Pegvisomant, 100 mg/kg, daily IGF1: ~80% reduction (Kaseb et al. 2022) Monotherapy-reduced tumour growth; reduction was more pronounced when combined with sorafenib Gastric SUN-16 (↓) Pegvisomant, 250 mg/kg, daily IGF-1: not described (Meng et al. 2022) Monotherapy: inhibition of tumour growth Pancreatic PANC1 (↓) Pegvisomant, 10 mg/kg/day; Compound G, 10 mg/kg/day IGF1: not described (Brody et al. 2021) Monotherapy: PEG and compound G decreased tumour growth GEM combined with PEG or compound G was more efficacious Breast MCF-7 (↓) GHR/PRLR neutralising mAb; 15 or 30 mg/kg, twice weekly IGF1: not described (Chen et al. 2020) T-47D (↓) Monotherapy: inhibited the growth of T-47D and MCF-7 Breast MDA-MB-231 (↓) Small-molecule BM 001–003, 1 and 5 mg/kg, 3 times per week IGF1: 73% reduction (van der Velden et al. 2022)Monotherapy: all three reduced tumour growth; BM001 was most effective (↓) indicates cell lines for which efficacy with GHR antagonism was observed either as a single agent or in combination therapy, while (–) indicates no effect.
Inhibition:Article Title: Targeting growth hormone in cancer: future perspectives.
Article Snippet: While results from genetic studies are persuasive, deficiency in GH signalling, for example, through Gh1/Ghr gene disruption or constitutive expression of a GHR/Ghr antagonist, would be expected to affect initial tumour establishment and growth prior to Downloaded from Bioscientifica.com at 10/07/2023 01:32:49AM via free access https://erc.bioscientifica.com © 2023 the author(s) Printed in Great Britain Published by Bioscientifica Ltd.https://doi.org/10.1530/ERC-23-0033 Prostate Pten-mutant mouse prostate cancer cell (↓) Pegvisomant, 100 mg/kg, 3 times per week IGF1: 18% reduction (3 days after the final injection) (Unterberger et al. 2022) Monotherapy-reduced Ptenmutant prostate tumour growth Hepatocellular HepG2 (↓) Pegvisomant, 100 mg/kg, daily IGF1: ~80% reduction (Kaseb et al. 2022) Monotherapy-reduced tumour growth; reduction was more pronounced when combined with sorafenib Gastric SUN-16 (↓) Pegvisomant, 250 mg/kg, daily IGF-1: not described (Meng et al. 2022) Monotherapy: inhibition of tumour growth Pancreatic PANC1 (↓) Pegvisomant, 10 mg/kg/day; Compound G, 10 mg/kg/day IGF1: not described (Brody et al. 2021) Monotherapy: PEG and compound G decreased tumour growth GEM combined with PEG or compound G was more efficacious Breast MCF-7 (↓) GHR/PRLR neutralising mAb; 15 or 30 mg/kg, twice weekly IGF1: not described (Chen et al. 2020) T-47D (↓) Monotherapy: inhibited the growth of T-47D and MCF-7 Breast MDA-MB-231 (↓) Small-molecule BM 001–003, 1 and 5 mg/kg, 3 times per week IGF1: 73% reduction (van der Velden et al. 2022)Monotherapy: all three reduced tumour growth; BM001 was most effective (↓) indicates cell lines for which efficacy with GHR antagonism was observed either as a single agent or in combination therapy, while (–) indicates no effect.
Multiple Displacement Amplification:Article Title: Targeting growth hormone in cancer: future perspectives.
Article Snippet: While results from genetic studies are persuasive, deficiency in GH signalling, for example, through Gh1/Ghr gene disruption or constitutive expression of a GHR/Ghr antagonist, would be expected to affect initial tumour establishment and growth prior to Downloaded from Bioscientifica.com at 10/07/2023 01:32:49AM via free access https://erc.bioscientifica.com © 2023 the author(s) Printed in Great Britain Published by Bioscientifica Ltd.https://doi.org/10.1530/ERC-23-0033 Prostate Pten-mutant mouse prostate cancer cell (↓) Pegvisomant, 100 mg/kg, 3 times per week IGF1: 18% reduction (3 days after the final injection) (Unterberger et al. 2022) Monotherapy-reduced Ptenmutant prostate tumour growth Hepatocellular HepG2 (↓) Pegvisomant, 100 mg/kg, daily IGF1: ~80% reduction (Kaseb et al. 2022) Monotherapy-reduced tumour growth; reduction was more pronounced when combined with sorafenib Gastric SUN-16 (↓) Pegvisomant, 250 mg/kg, daily IGF-1: not described (Meng et al. 2022) Monotherapy: inhibition of tumour growth Pancreatic PANC1 (↓) Pegvisomant, 10 mg/kg/day; Compound G, 10 mg/kg/day IGF1: not described (Brody et al. 2021) Monotherapy: PEG and compound G decreased tumour growth GEM combined with PEG or compound G was more efficacious Breast MCF-7 (↓) GHR/PRLR neutralising mAb; 15 or 30 mg/kg, twice weekly IGF1: not described (Chen et al. 2020) T-47D (↓) Monotherapy: inhibited the growth of T-47D and MCF-7 Breast MDA-MB-231 (↓) Small-molecule BM 001–003, 1 and 5 mg/kg, 3 times per week IGF1: 73% reduction (van der Velden et al. 2022)Monotherapy: all three reduced tumour growth; BM001 was most effective (↓) indicates cell lines for which efficacy with GHR antagonism was observed either as a single agent or in combination therapy, while (–) indicates no effect.
Control:Article Title: Targeting growth hormone in cancer: future perspectives.
Article Snippet: While results from genetic studies are persuasive, deficiency in GH signalling, for example, through Gh1/Ghr gene disruption or constitutive expression of a GHR/Ghr antagonist, would be expected to affect initial tumour establishment and growth prior to Downloaded from Bioscientifica.com at 10/07/2023 01:32:49AM via free access https://erc.bioscientifica.com © 2023 the author(s) Printed in Great Britain Published by Bioscientifica Ltd.https://doi.org/10.1530/ERC-23-0033 Prostate Pten-mutant mouse prostate cancer cell (↓) Pegvisomant, 100 mg/kg, 3 times per week IGF1: 18% reduction (3 days after the final injection) (Unterberger et al. 2022) Monotherapy-reduced Ptenmutant prostate tumour growth Hepatocellular HepG2 (↓) Pegvisomant, 100 mg/kg, daily IGF1: ~80% reduction (Kaseb et al. 2022) Monotherapy-reduced tumour growth; reduction was more pronounced when combined with sorafenib Gastric SUN-16 (↓) Pegvisomant, 250 mg/kg, daily IGF-1: not described (Meng et al. 2022) Monotherapy: inhibition of tumour growth Pancreatic PANC1 (↓) Pegvisomant, 10 mg/kg/day; Compound G, 10 mg/kg/day IGF1: not described (Brody et al. 2021) Monotherapy: PEG and compound G decreased tumour growth GEM combined with PEG or compound G was more efficacious Breast MCF-7 (↓) GHR/PRLR neutralising mAb; 15 or 30 mg/kg, twice weekly IGF1: not described (Chen et al. 2020) T-47D (↓) Monotherapy: inhibited the growth of T-47D and MCF-7 Breast MDA-MB-231 (↓) Small-molecule BM 001–003, 1 and 5 mg/kg, 3 times per week IGF1: 73% reduction (van der Velden et al. 2022)Monotherapy: all three reduced tumour growth; BM001 was most effective (↓) indicates cell lines for which efficacy with GHR antagonism was observed either as a single agent or in combination therapy, while (–) indicates no effect.
Clinical Proteomics:Article Title: Targeting growth hormone in cancer: future perspectives.
Article Snippet: While results from genetic studies are persuasive, deficiency in GH signalling, for example, through Gh1/Ghr gene disruption or constitutive expression of a GHR/Ghr antagonist, would be expected to affect initial tumour establishment and growth prior to Downloaded from Bioscientifica.com at 10/07/2023 01:32:49AM via free access https://erc.bioscientifica.com © 2023 the author(s) Printed in Great Britain Published by Bioscientifica Ltd.https://doi.org/10.1530/ERC-23-0033 Prostate Pten-mutant mouse prostate cancer cell (↓) Pegvisomant, 100 mg/kg, 3 times per week IGF1: 18% reduction (3 days after the final injection) (Unterberger et al. 2022) Monotherapy-reduced Ptenmutant prostate tumour growth Hepatocellular HepG2 (↓) Pegvisomant, 100 mg/kg, daily IGF1: ~80% reduction (Kaseb et al. 2022) Monotherapy-reduced tumour growth; reduction was more pronounced when combined with sorafenib Gastric SUN-16 (↓) Pegvisomant, 250 mg/kg, daily IGF-1: not described (Meng et al. 2022) Monotherapy: inhibition of tumour growth Pancreatic PANC1 (↓) Pegvisomant, 10 mg/kg/day; Compound G, 10 mg/kg/day IGF1: not described (Brody et al. 2021) Monotherapy: PEG and compound G decreased tumour growth GEM combined with PEG or compound G was more efficacious Breast MCF-7 (↓) GHR/PRLR neutralising mAb; 15 or 30 mg/kg, twice weekly IGF1: not described (Chen et al. 2020) T-47D (↓) Monotherapy: inhibited the growth of T-47D and MCF-7 Breast MDA-MB-231 (↓) Small-molecule BM 001–003, 1 and 5 mg/kg, 3 times per week IGF1: 73% reduction (van der Velden et al. 2022)Monotherapy: all three reduced tumour growth; BM001 was most effective (↓) indicates cell lines for which efficacy with GHR antagonism was observed either as a single agent or in combination therapy, while (–) indicates no effect.
|
